Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Supplement urolithin a tested for blood sugar boost in older adults

NCT ID NCT06274749

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Sep 21, 2026 · Updated 60 times

Summary

This study tests whether urolithin A, a natural supplement, can improve how the body releases insulin and controls blood sugar in healthy adults aged 55 and older with a BMI of 27 or higher. Over 8 weeks, 180 participants will take either urolithin A or a placebo daily. Researchers will measure insulin and hormone responses to sugar drinks, continuous glucose monitoring, and exercise tests.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Urolithin A (a dietary supplement)
What this could lead to
If it works, this could point toward a simple supplement to help older adults maintain healthy blood sugar levels and reduce diabetes risk.
What could go wrong
This is an early-stage trial in healthy volunteers, so results may not apply to people with diabetes. The supplement may show no benefit over placebo.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 180 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Mar 2027

An estimate. End dates often move.

Lead sponsor

A government research agency

The lead sponsor is the US National Institutes of Health.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 to 100 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

* INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: * Provision of signed and dated informed consent form. * Stated willingness to comply with all study procedures and availably for the duration of the study. * Male or female, age \>= 55 years. * Able to speak and read English. (We do not have ready access to interpreters of different languages at the NIA Clinical Unit). * BMI \>= 27. * Ability to take oral medication and be willing to adhere to the daily regimen. * Ability to perform walking and treadmill tests without physical limitations. * In good general health, as evidenced by medical history/physical exam/laboratory results. EXCLUSION CRITERIA: An individual who meets any of the following criteria will be excluded from participation in this study: * History of diabetes requiring treatment with any glucose lowering drug(s). * Fasting glucose \>= 126 on screening visit. * Is on treatment with an investigational drug or other intervention within 8 weeks of enrollment. * Hospitalization within 12 months for myocardial infarction, coronary revascularization or bypass surgery or stroke. * History of autoimmune disease, e.g., Hashimoto s thyroiditis, Myasthenia Gravis or Rheumatoid Arthritis. * Uncontrolled thyroid disease. * Chronic liver disease indicated by medical history or one of the liver enzymes greater than 2 times the normal range. * History of chronic kidney disease or GFR \<60 mL/min/1.73 m\^2. * Anemia (defined as hemoglobin level \<12 g/dl for men or \< 11 g/dl for women). * Poor venous access. * Uncontrolled hypertension as judged by the Investigator. * History of significant GI disease, e.g., IBS, Crohn s disease. * Active cancer or has had treatment for cancer in the last 1 year. * Medical condition requiring absolute and continuous need for long-term treatment with antibiotics, corticosteroids, immunosuppressors. * Currently pregnant or a nursing mother due to possible changes in hormones and metabolism. * History of, or laboratory evidence of HIV virus infection at Screening Visit. * History of, or laboratory evidence of Hepatitis B or C at Screening Visit. * Positive urine drug screen at Screening Visit (unless taking prescribed medication and at the discretion of the PI). * Reports claustrophobia and/or is not eligible to have an MRI as per the MRI eligibility form. * Weight \>= 300 lbs (MRI scanner weight limit). * Hip or knee replacement or other medical condition that prevents MRI research scans from being performed. * Diagnosed with cognitive impairment that clearly prevents the participant from providing informed consent. * Current smoker or tobacco use in the past year. * History of substance abuse, including marijuana use in the past year. * On average, consumes more than 1 alcoholic drink per day. * Any other condition which in the investigator s opinion may adversely affect the subject s ability to complete the study or its measures or which may pose significant risk to the subject.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Healthy volunteer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Insulin Resistance

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • National Institute of Aging, Clinical Research Unit

    RECRUITING

    Baltimore, Maryland, 21224, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.